Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
July 2025—ARUP Laboratories now provides a blood test for phosphorylated tau 217 to assist in identifying whether symptoms of cognitive decline in patients ages 60 years and older are related to Alzheimer’s disease pathology.
July 2025—BD announced FDA 510(k) clearance for the BD Phoenix M50 automated microbiology solution and BDXpert system on the BD Synapsys informatics solution, leveraging rapid identification and antimicrobial susceptibility testing algorithms to assist in interpreting complex diagnostic data to help ensure accurate and reliable diagnoses related to antimicrobial resistance. BDXpert is an automated, rule-based system that analyzes ID and AST results from the BD Phoenix M50 system.
July 2025—Techcyte announced the launch of its wet mount iodine solution for research use only in the United States. The AI-assisted screening tool is designed to help users locate, count, and preclassify parasites from iodine-stained fecal slides. The solution is part of Techcyte’s Fusion parasitology suite, which includes the company’s trichrome and modified acid fast solutions.
July 2025—BioMérieux has agreed to acquire Day Zero Diagnostics, an infectious disease diagnostics company, with the aim of enhancing BioMérieux’s capabilities in next-generation sequencing and rapid diagnostics. Day Zero Diagnostics, based in Watertown, Mass., has developed technologies that integrate direct from whole blood sample preparation, sequencing, and advanced infectious disease and antimicrobial susceptibility testing analytics. The sequencing-based rapid diagnostic in development can identify the species and antibiotic resistance profile of a bacterial pathogen within hours.
July 2025—Diasorin has received 510(k) clearance from the FDA for its Liaison Plex Gram-positive blood culture assay. The assay detects 17 targets (13 Gram-positive bacteria and four relevant resistance gene targets) in less than two hours and features Diasorin’s proprietary NanoGrid technology, which allows the detection of nucleic acids without the need for conventional amplification reactions.
July 2025—Ibex Medical Analytics reports that a study conducted at Ohio State University Wexner Medical Center confirms that Ibex Breast, an AI-powered diagnostic support solution, significantly improves accuracy and efficiency in evaluating breast pathology cases (Tahir M, et al. Clin Breast Cancer. Published online March 26, 2025). The study analyzed 104 real-world breast biopsies, including invasive and microinvasive carcinomas, ductal carcinoma in situ, atypical lobular hyperplasia, and other benign lesions. Three breast pathologists independently reviewed each case digitally, with and without the support of Ibex Breast. Results demonstrated that when using AI, diagnostic accuracy improved from 97.1 percent to 100 percent, with previously missed precancerous lesions, such as lobular neoplasia and microcalcifications, correctly identified.
July 2025—Sysmex America has received FDA clearance for its CN-6000 automated blood coagulation analyzer. The clearance also covers reagent products for prothrombin time seconds and PT INR (Dade Innovin), activated partial thromboplastin time (Dade Actin FSL), fibrinogen (Dade thrombin reagent), antithrombin (Innovance antithrombin), and D-dimer (Innovance D-dimer). Sysmex has also received Health Canada license for the CN-6000 as well as its CN-3000 automated blood coagulation analyzer.
July 2025—BD announced the worldwide commercial launch of its FacsDiscover A8 cell analyzer. It features BD SpectralFX technology, which maximizes the number of colors that can be used in flow cytometry; BD CellView image technology, which enables high-speed fluorescent and label-free imaging of single cells; and intuitive software workflows that allow for effective management of large data sets. The analyzer pairs with BD FacsDiscover cell sorters and BD reagents.
July 2025—Empire Genomics and BioDot have partnered to launch a line of hematology-focused FISH probe panels and controls. The BDot Probe line is preoptimized, ready to use, and validated for performance on the BioDot CellWriter S platform. The initial release of the panels includes targeted solutions for FISH analysis of a range of hematologic malignancies, including multiple myeloma, myelodysplastic syndromes, chronic myelogenous leukemia, acute myeloid leukemia, acute lymphoblastic leukemia, and other common hematologic disorders.
July 2025—Agilent Technologies has launched its Agilent InfinityLab Pro iQ series of mass detectors for liquid chromatography. The series includes the InfinityLab Pro iQ and InfinityLab Pro iQ Plus and supports applications such as mass confirmation, impurity profiling, biomolecule characterization, trace contaminant detection, and compound purification. The Pro iQ system, with a mass range of m/z 2–1,600, is optimized for small molecule analysis, while the Pro iQ Plus system is engineered for high-end applications and has a mass range of m/z 2–3,000.
